ArticleJournal for immunotherapy of cancer2014

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.

Shailender Bhatia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.